强化序贯阿托伐他汀钙治疗急性脑梗死临床研究

Clinical Study on Sequential Intensified Atorvastatin Calcium to Treat Acute Cerebral Infarction

目的观察强化、序贯阿托伐他汀钙治疗急性脑梗死的临床疗效。方法选择2012年6月～2013年6月来自本院神经内科就诊的100例脑梗死患者入组，患者均在发病后24小时内入院并符合急性缺血性脑卒中的临床诊断，随机分为治疗组与对照组，治疗组50例，对照组50例，治疗组加用阿托伐他汀钙40mg，口服，每天一次，强化治疗14天后，改20mg，口服，序贯治疗21天。对照组不使用阿托伐他汀钙。两组患者的活血化瘀、抗血小板聚集、脑细胞代谢等神经科治疗药物、康复方案相同，分别在治疗前和治疗后5周进行NIHSS（美国国立卫生院脑卒中量表）神经功能缺损评分、日常生活活动能力（activitiesofdailylivingADL）量表评分以及改良Rankinj量表（ModifiedRankinScale，MRS）评分，进行效疗评定。结果治疗后，治疗组的NIHSS评分、ADL评分、改良Rankinj量表评分均有明显降低，较对照组有显著差异（P〈0．05）。治疗组临床治疗效果优于对照组（P〈0．05）。结论强化、序贯阿托伐他汀钙治疗脑梗死有显著临床效果。

Objective To observe the clinical effects of atorvastatin calcium in strengthened and sequential used for treated of acute cerebral infarction. Methods From June 2012 to June 2013,100 eases of patient diagnosed with cerebral infarction were enrolled at department of internal neurology in our hospital. They were randomly divided into treatment group （n=50） and control group （n=50）. The treatment group was administrated atorvastatin calcium 40mg, oral, once a day. And after 14 days, it was changed to 20mg, oral, sequential therapy for 21 days. The control group was not given atorvastatin calcium. The blood circulation, anti-platelet aggregation, brain cell metabolism and other neurological treatment drug, and rehabilitation protocol were the same in two groups. The nerve function defect （NIHSS score）, ability of daily life （ADL scale） and modified Rankin scale were evaluated before treatment and after 5 weeks. Also, the clinical effects were compared. Results After the treatment, the NIHSS score, ADL score and the modified Rankin scale score in treatment group were lower than those in the control group, the differences were statistically significant （P〈0.05）. The effect of clinical treatment in treatment group was better than the control group （P〈0.05） Conclusion Atorvastatin calcium in strengthened and sequential using has significant clinical effect on treating cerebral infarction.